Even though the recent progress in understanding gene profile and pathways involved in NAFLD has suggested the possible role of targeted therapies (i.e., FXR agonists and PPAR agonists), there is no approved therapy for NAFLD (7). Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.